Targets › TL1A
3 programs from 3 companies in 11 trials: 6 Phase 2, 3 Phase 3, 2 Phase 1; Immunology, Other; next expected readout Jan 2027.
Cytokine that signals through TNFRSF25 receptor. Functions as a T-cell costimulator, that increases IL-2 responsiveness and secretion of pro-inflammatory cytokines which enhances T-cell activation, proliferation and the survival of activated T-cells. (UniProt, O95150)
Open in Phaseline: the race on TL1A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Merck & Co. (MSD) | Tulisokibart Humanized monoclonal antibody that binds tumor necrosis factor-like cytokine 1A (TL1A) | TL1A | Phase 3 | Crohn's Disease; Ulcerative Colitis; Crohn Disease; Psoriatic Arthritis … | Feb 2027 |
| Biocad | BCD-261 Anti-TL1A human monoclonal antibody | TNFSF15, TL1A | Phase 2 | Ulcerative Colitis (UC); Crohn's Disease (CD); Healthy | Jan 2027 |
| SPH-BIOCAD (HK) | BCD-261 anti-TL1A human monoclonal antibody | TL1A | Phase 1 | Healthy Adult Participants | Mar 2027 |
Ulcerative Colitis (UC) (1) Crohn's Disease (CD) (1) Healthy (1) Crohn's Disease (1) Ulcerative Colitis (1) Crohn Disease (1) Psoriatic Arthritis (1) Radiographic Axial Spondyloarthritis (1) Hidradenitis Suppurativa (1) Arthritis, Rheumatoid (1) Healthy Adult Participants (1)
small molecule (2), antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.